Pre-earnings brief
Reports
Tue, Nov 10, 2026
Est. EPS
—
Est. revenue
—
Implied move
±18.8%
EPS beat rate
75%
Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for various health conditions. Operating in the healthcare sector, its work is particularly relevant as the demand for effective therapies continues to grow amid an aging population and increasing healthcare needs.
Last quarter
In Q2-2026, Mineralys reported an EPS of -$2.85, significantly missing expectations. The stock reacted slightly negatively the following day, indicating investor disappointment.
EPS beat streak
0Q
EPS beat rate
75%
Avg EPS surprise
-41.45%
Avg 1-day reaction
+4.68%
Overall expectations are mixed as the company has a history of beating EPS estimates but recently reported a significant miss. Investors will be closely watching for any signs of recovery or continued struggles.
Bull case
If Mineralys can demonstrate improved operational efficiency or new product developments, it could lead to a strong rebound in stock performance.
Bear case
Continued losses and lack of revenue growth could further erode investor confidence, leading to a more significant decline in stock value.
The print will turn on these.
Q1
What will the EPS be for Q3-2026, and how does it compare to previous quarters?
Given the significant miss last quarter, investors will be keen to see if the company can stabilize its earnings.
Q2
What are the revenue expectations for this quarter?
Revenue growth is crucial for the company's future, and any signs of improvement could positively influence investor sentiment.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±11.1%
Why consensus could be wrong
The market may be underestimating the potential for a turnaround in performance, as past trends show a tendency for recovery after significant misses.
Supporting evidence
The company has a 75% EPS beat rate historically, indicating potential for positive surprises.
Options are pricing a 21.89% move, suggesting that traders expect significant volatility, which could be a sign of upcoming positive news.
Key risk
If the EPS comes in better than expected, it could shift the narrative significantly.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether the company can turn around its financial performance after a disappointing last report.
Bull confirmed if
An EPS improvement to -$1.50 or better would confirm the bull case.
Bear confirmed if
An EPS of worse than -$3.00 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±21.89%
Historical Avg
±5.6%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.
Options are pricing ±18.8% while MLYS has averaged ±5.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
68.2%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 12 of 30 (40%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 30 faded and 18 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.6%, with a raw directional average of +2.2% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.9M
75,000 sh
1 insider
Net
$1.9M
Net selling
Most Active Insiders· 1 open-market trade
$1.9M
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Mineralys beats expectations, history suggests a potential stock increase of around 5.22%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately 3.04%, reflecting ongoing concerns about profitability.
The lines on the call that would change the story.
Recent Transactions
Sep 30, 2026 · @ $25.46
75,000 sh
$1.9M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.